Source: Zolmax News

LogicBio: Equities Analysts Offer Predictions for LogicBio Therapeutics Inc's Q2 2020 Earnings (NASDAQ:LOGC)

LogicBio Therapeutics Inc (NASDAQ:LOGC) - Jefferies Financial Group raised their Q2 2020 earnings per share (EPS) estimates for LogicBio Therapeutics in a research note issued to investors on Wednesday, May 13th. Jefferies Financial Group analyst M. Raycroft now anticipates that the company will post earnings per share of ($0.42) for the quarter, up from their [...]

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Frederic Chereau's photo - President & CEO of LogicBio

President & CEO

Frederic Chereau

CEO Approval Rating

82/100

LogicBio is a biotechnology company that develops genetic medicines to treat rare pediatric diseases. Read more